Geron stock gains in wake of Merck deal

Shares of Geron surged this morning after the biotech announced that it had inked a collaboration deal with Merck to develop a cancer vaccine that targets telomerase. Telomerase promotes cancer growth. Details were in short supply, but Geron gains an upfront payment, milestones and a pledge by Merck to take an equity stake in its next round of venture capital.

- read this AP story for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.